Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

XGN Exagen Inc. Common Stock
$3.77 -8.72% -0.36
Notify me if price changes either direction
Interactive Brokers Logotype

Buy XGN stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades

Exagen Inc. Common Stock (XGN)

Loading

Key Stats

Market cap. 96.2M
Enterprise value 105.7M
Trailing PE -4.0430107424336
Forward PE -8.26
PEG Ratio 0.10612903198888
Enterprise to EBITDA -8.779
Enterprise to revenue 1.461
Price to book MRQ 7.6199265
Price to sales TTM 1.4575108

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-06-30
Revenue (TTM) 72.3M
EBITDA -12035000
Diluted EPS TTM -0.76
Total Cash (MRQ) 28.1M
Current ratio (MRQ) 3.46
Operating Cash Flow (TTM) -13625000

XGN trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent XGN News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.